Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Systemic therapy for gallbladder cancer.

Javle M, Zhao H, Abou-Alfa GK.

Chin Clin Oncol. 2019 Aug;8(4):44. doi: 10.21037/cco.2019.08.14.

2.

Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer.

Perri G, Prakash L, Wang H, Bhosale P, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay E, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG.

Ann Surg. 2019 Jul 3. doi: 10.1097/SLA.0000000000003442. [Epub ahead of print]

PMID:
31274655
3.

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.

Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ.

JAMA Oncol. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270.

PMID:
30998813
4.

Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma.

Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S.

Radiother Oncol. 2019 Apr;133:54-61. doi: 10.1016/j.radonc.2018.10.041. Epub 2019 Jan 16.

PMID:
30935582
5.

Preoperative drainage for perihilar cholangiocarcinoma.

Odisio BC, Krampitz GW, Murthy R, Mahvash A, Javle M, Vauthey JN.

Lancet Gastroenterol Hepatol. 2019 Jan;4(1):10-11. doi: 10.1016/S2468-1253(18)30345-5. Epub 2018 Dec 6. No abstract available.

PMID:
30527574
6.

Genetic landscape of gallbladder cancer: Global overview.

Mehrotra R, Tulsyan S, Hussain S, Mittal B, Singh Saluja S, Singh S, Tanwar P, Khan A, Javle M, Hassan MM, Pant S, De Aretxabala X, Sirohi B, Rajaraman P, Kaur T, Rath GK.

Mutat Res. 2018 Oct - Dec;778:61-71. doi: 10.1016/j.mrrev.2018.08.003. Epub 2018 Aug 23. Review.

PMID:
30454684
7.

Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer.

Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, Javle M, Glenjen NI, Abelseth BK, Gilje B, Nordgård O.

J Transl Med. 2018 Nov 6;16(1):300. doi: 10.1186/s12967-018-1677-2.

8.

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.

Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F.

Cancer. 2019 Feb 1;125(3):463-472. doi: 10.1002/cncr.31812. Epub 2018 Nov 1.

PMID:
30383888
9.

First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.

Gulhati P, Prakash L, Katz MHG, Wang X, Javle M, Shroff R, Fogelman D, Lee JE, Tzeng CD, Lee JH, Weston B, Tamm E, Bhosale P, Koay EJ, Maitra A, Wang H, Wolff RA, Varadhachary GR.

Ann Surg Oncol. 2019 Feb;26(2):619-627. doi: 10.1245/s10434-018-6807-9. Epub 2018 Oct 15.

PMID:
30324485
10.

A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.

Fountzilas C, Javle M, Tan W, Ma Y, Fetterly G, Iyer R, Johnson C.

Cancer. 2018 Oct 1;124(19):3890-3899. doi: 10.1002/cncr.31676. Epub 2018 Oct 9.

11.

Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.

Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA.

Gastroenterology. 2019 Jan;156(1):108-118.e4. doi: 10.1053/j.gastro.2018.09.022. Epub 2018 Sep 19.

12.

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma.

Elganainy D, Holliday EB, Taniguchi CM, Smith GL, Shroff R, Javle M, Raghav K, Kaseb A, Aloia TA, Vauthey JN, Tzeng CD, Herman JM, Koong AC, Krishnan SX, Minsky BD, Crane CH, Das P, Koay EJ.

Cancer Med. 2018 Oct;7(10):4880-4892. doi: 10.1002/cam4.1734. Epub 2018 Aug 27.

13.

A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma.

Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB.

Clin Cancer Res. 2018 Dec 1;24(23):5883-5894. doi: 10.1158/1078-0432.CCR-17-3668. Epub 2018 Aug 6.

PMID:
30082477
14.

Liver transplantation for locally advanced intrahepatic cholangiocarcinoma - Authors' reply.

Lunsford KE, Javle M, Gaber AO, Vauthey JN, Ghobrial RM.

Lancet Gastroenterol Hepatol. 2018 Aug;3(8):529-530. doi: 10.1016/S2468-1253(18)30167-5. No abstract available.

PMID:
30047444
15.

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M.

J Hematol Oncol. 2018 May 30;11(1):71. doi: 10.1186/s13045-018-0616-2.

16.

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.

Finn RS, Ahn DH, Javle MM, Tan BR Jr, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS.

Invest New Drugs. 2018 Dec;36(6):1037-1043. doi: 10.1007/s10637-018-0600-2. Epub 2018 May 22.

PMID:
29785570
17.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

18.

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.

Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V.

Mol Cancer Ther. 2018 Jul;17(7):1595-1601. doi: 10.1158/1535-7163.MCT-17-1107. Epub 2018 Apr 13.

19.

Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer.

Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, Liu X, Liu CG, Wu X, Wang H, Li D, Prakash LR, Katz MH, Kang Y, Kim M, Fleming JB, Fogelman D, Javle M, Maitra A, Hung MC.

Cancer Cell. 2018 Apr 9;33(4):752-769.e8. doi: 10.1016/j.ccell.2018.02.012. Epub 2018 Mar 29.

20.

Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.

Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM; Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC).

Lancet Gastroenterol Hepatol. 2018 May;3(5):337-348. doi: 10.1016/S2468-1253(18)30045-1. Epub 2018 Mar 13. Erratum in: Lancet Gastroenterol Hepatol. 2018 Jun;3(6):e3.

PMID:
29548617
21.

Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension.

Sheth RA, Sabir SH, Parmet P, Amin R, Kuban JD, Huang SY, Mahvash A, Fogelman D, Javle M, Wallace MJ.

Oncologist. 2018 Jun;23(6):712-718. doi: 10.1634/theoncologist.2017-0337. Epub 2017 Dec 28.

22.

Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.

Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ.

Oncologist. 2018 Mar;23(3):277-e26. doi: 10.1634/theoncologist.2017-0568. Epub 2017 Dec 19.

23.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

24.

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.

Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA.

Oncotarget. 2017 Aug 3;8(50):87163-87173. doi: 10.18632/oncotarget.19897. eCollection 2017 Oct 20.

25.

Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.

Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H.

Ann Oncol. 2018 Jan 1;29(1):223-229. doi: 10.1093/annonc/mdx542.

26.

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

Chun YS, Javle M.

Cancer Control. 2017 Jul-Sep;24(3):1073274817729241. doi: 10.1177/1073274817729241. Review.

27.

4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C.

Clin Cancer Res. 2017 Dec 1;23(23):7263-7275. doi: 10.1158/1078-0432.CCR-17-0831. Epub 2017 Sep 25.

28.

DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.

Golan T, Javle M.

J Natl Compr Canc Netw. 2017 Aug;15(8):1063-1069. doi: 10.6004/jnccn.2017.0133. Review.

PMID:
28784866
29.

Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.

Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG.

JAMA Surg. 2017 Nov 1;152(11):1048-1056. doi: 10.1001/jamasurg.2017.2227.

30.

Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma.

Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO.

Clin Gastroenterol Hepatol. 2017 Nov;15(11):1791-1799. doi: 10.1016/j.cgh.2017.05.036. Epub 2017 Jun 1.

31.

Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells.

Lapin M, Tjensvoll K, Oltedal S, Javle M, Smaaland R, Gilje B, Nordgård O.

BMC Cancer. 2017 May 31;17(1):390. doi: 10.1186/s12885-017-3385-3.

32.

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.

Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS.

Clin Cancer Res. 2017 Sep 15;23(18):5648-5656. doi: 10.1158/1078-0432.CCR-17-0291. Epub 2017 May 23.

33.

Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?

Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH.

Hepatobiliary Surg Nutr. 2017 Apr;6(2):105-116. doi: 10.21037/hbsn.2017.01.16. Review.

34.

Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.

Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M.

Oncologist. 2017 Jul;22(7):804-810. doi: 10.1634/theoncologist.2016-0415. Epub 2017 May 9. Review.

35.

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.

Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S.

Br J Cancer. 2017 Mar 14;116(6):697-702. doi: 10.1038/bjc.2017.19. Epub 2017 Feb 9.

36.

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A.

Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2.

37.

Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater.

Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG.

Ann Surg Oncol. 2017 Jul;24(7):2031-2039. doi: 10.1245/s10434-017-5777-7. Epub 2017 Jan 25.

PMID:
28124275
38.

Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.

Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ.

J Gastrointest Oncol. 2016 Dec;7(6):819-827. doi: 10.21037/jgo.2016.11.11. No abstract available.

39.

Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?

Chadha AS, Liu G, Chen HC, Das P, Minsky BD, Mahmood U, Delclos ME, Suh Y, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH, Wang X, Thames H, Krishnan S.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):323-332. doi: 10.1016/j.ijrobp.2016.10.046. Epub 2016 Nov 8.

PMID:
28068240
40.

Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer.

Yamashita S, Passot G, Aloia TA, Chun YS, Javle M, Lee JE, Vauthey JN, Conrad C.

Br J Surg. 2017 Feb;104(3):267-277. doi: 10.1002/bjs.10415. Epub 2017 Jan 4.

PMID:
28052308
41.

Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients.

Yamashita S, Koay EJ, Passot G, Shroff R, Raghav KP, Conrad C, Chun YS, Aloia TA, Tao R, Kaseb A, Javle M, Crane CH, Vauthey JN.

Cancer. 2017 Apr 15;123(8):1354-1362. doi: 10.1002/cncr.30488. Epub 2016 Dec 16.

42.

Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.

Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ.

Cancer. 2017 May 15;123(6):1011-1017. doi: 10.1002/cncr.30445. Epub 2016 Nov 14.

43.

Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.

Jain A, Kwong LN, Javle M.

Curr Treat Options Oncol. 2016 Nov;17(11):58. Review.

PMID:
27658789
44.

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE.

J Gastrointest Surg. 2017 Jan;21(1):164-174. doi: 10.1007/s11605-016-3265-1. Epub 2016 Oct 24.

PMID:
27778257
45.

Molecular profiling of biliary tract cancer: a target rich disease.

Jain A, Javle M.

J Gastrointest Oncol. 2016 Oct;7(5):797-803. Review.

46.

Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality.

Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M, Crane CH, Koay EJ, Krishnan S, Das P, Minsky BD, Varadhachary G, Shroff R, Wolff R, Javle M, Overman MJ, Fogelman D, Aloia TA, Vauthey JN, Fleming JB, Katz MH.

J Gastrointest Surg. 2016 Dec;20(12):1975-1985. Epub 2016 Oct 11.

PMID:
27730398
47.

Biliary cancer: Utility of next-generation sequencing for clinical management.

Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J.

Cancer. 2016 Dec 15;122(24):3838-3847. doi: 10.1002/cncr.30254. Epub 2016 Sep 13.

48.

BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype.

Al-Shamsi HO, Anand D, Shroff RT, Jain A, Zuo M, Conrad C, Vauthey JN, Javle MM.

J Gastrointest Oncol. 2016 Aug;7(4):556-61. doi: 10.21037/jgo.2016.03.05.

49.

Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.

Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL, Bekaii-Saab T.

Cancer. 2016 Dec 1;122(23):3657-3666. doi: 10.1002/cncr.30247. Epub 2016 Aug 6. Erratum in: Cancer. 2017 Jun 15;123(12 ):2376.

50.

Laparoscopic Management of Gallbladder Cancer: A Stepwise Approach.

Yamashita S, Loyer E, Chun YS, Javle M, Lee JE, Vauthey JN, Conrad C.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):892-893. Epub 2016 Jul 25.

PMID:
27456958

Supplemental Content

Support Center